Clinical Trial Search

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Number of Subjects Boosted at Month 12 With Haemagglutinin-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 178 Participants

Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants

Primary: Number of Seasonal Influenza A and /or B Cases by Age Group, in Panama (Using the Data Reported Via National Influenza Surveillance Program) — 448; 120; 123; 47…

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number

Primary: Change in Intentions to Take Antivirals for Pandemic Flu — 8.29; 8.16; 8.23; 8.35 score on a scale — p=>.05

Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation. — 234…

Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42

Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants

Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI

Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects

Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections

Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants

Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069

Primary: Percent MMID — 0; 0; 20; 47 percentage of participants

Primary: Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab — 2; 4 participants — p=0.685

Primary: Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire…

Primary: Solicted Adverse Events — 8; 12; 13; 14 participants

Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…

Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants

Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 6; 24; 21 Participants

Primary: The Difference in Seroconversion/Immunogenicity Between rHA Formulated in an oil-in- Water Adjuvant (SE) Compared to a rHA Antigen Alone. — 83; 70; 9; 76 percentage of…

Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 0; 17 Participants

Primary: Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years — 69; 70; 61; 23 Participants

Primary: Initiate Antiviral Therapy Within 48 Hours of Symptom Onset — 8 Participants

Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Two Strains of Influenza Disease. — 11.3; 9.7; 10.2; 8.8 Titer

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease — NA; NA; NA; NA Titer